AXL and non-small cell lung carcinoma: Patients with NSCLC were the major focus of this dose-optimization study as initial studies showed promise in this patient population, and patients were stratified by EGFR mutation status based on the potential role of AXL overexpression in acquired resistance to TKI therapy (5).